ATTENTION/WARNING - NE PAS DÉPOSER ICI/DO NOT SUBMIT HERE

Ceci est la version de TEST de DIAL.mem. Veuillez ne pas soumettre votre mémoire sur ce site mais bien à l'URL suivante: 'https://thesis.dial.uclouvain.be'.
This is the TEST version of DIAL.mem. Please use the following URL to submit your master thesis: 'https://thesis.dial.uclouvain.be'.
 

Le lasmiditan : l’agoniste 5-HT1F sélectif prometteur pour le traitement de crise de la migraine

Martegani, Clara
(2022)

Files

Martegani_Clara_32421500_2021-2022.pdf
  • UCLouvain restricted access
  • Adobe PDF
  • 2.98 MB
Download not available

Details

Supervisors
Dessy, Chantal
Faculty
Faculté de pharmacie et des sciences biomédicales
Degree label
Master [120] en sciences pharmaceutiques, à finalité spécialisée
Abstract
Migraine is a debilitating neurovascular disease and a current public health issue. An appropriate and early treatment of acute migraine is essential to avoid further evolution to chronic migraine. Triptans have been for many years the first choice medication for acute migraine. Recently, new molecules have been approved in the United States, including lasmiditan. Lasmiditan is the first 5-HT1F selective agonist to be approved for the treatment of acute migraine. By using a different receptor compared to triptans, lasmiditan could be a valid alternative for patients who cannot use triptans. The objective of this thesis is to discuss lasmiditan’s therapeutic plus-value compared to other acute migraine drugs based on migraine’s physiopathology as well as different clinical trials and meta-analysis.

Citations

  • APA

Martegani, C. (2022). Le lasmiditan : l’agoniste 5-HT1F sélectif prometteur pour le traitement de crise de la migraine. https://dial-mem.test.bib.ucl.ac.be/handle/2078.2/29660